Preclinical Properties of N⁴-Hexadecyl- and N⁴- Octadecyl-1-β-D-Arabinofuranosylcytosine in Liposomal Preparations

References

• Plunkett W., Gandhi V. Cellular pharmacodynamics of anticancer drugs. Semin. Oncol. 1993; 20: 50
   PubMed Web of Science ®Google Scholar
• Ho D. H., Frei E., III. Clinical pharmacology of 1-β-D-arabinofuranosyl cytosine. Clin. Pharmacol. Therap. 1971; 12: 944
   PubMed Web of Science ®Google Scholar
• Frei E., III, Bickers J. N., Hewlett J. S., Lane M., Leary W. V., Talley R. W. Dose schedule and antitumor studies of arabinosyl cytosine. Cancer Res. 1969; 29: 1325
   PubMed Web of Science ®Google Scholar
• Momparler R. L. A model for the chemotherapy of acute leukemia with 1-β-D-arabinofuranosylcytosine. Cancer Res. 1974; 34: 1775
   PubMed Web of Science ®Google Scholar
• Bolwell B. J., Cassileth P. A., Gale R. P. High dose cytarabine: a review. Leukemia 1988; 2: 253
   PubMed Web of Science ®Google Scholar
• Kreis W., Budman D. R., Chan K., Allen S. L., Schulman P., Lichtman S., Weiselberg L., Schuster M., Freeman J., Akerman S., Attas L., Vinciguerra V. Therapy of refractory/relapsed acute leukemia with cytosine arabinoside plus tetrahydrouridine (an inhibitor of cytidine deaminase) — a pilot study. Leukemia 1991; 5: 991
   PubMed Web of Science ®Google Scholar
• Laliberte J., Marquez V. E., Momparler R. L. Potent inhibitors for the deamination of cytosine arabinoside and 5-aza-2′-deoxycytidine by human cytidine deaminase. Cancer Chemother. Pharmacol. 1992; 30: 7
   PubMed Web of Science ®Google Scholar
• Driscoll J. S., Marquez V. E., Plowman J., Liu P. S., Kelley J. A., Barchi J. J. Antitumor properties of 2(1H)-pyrimidinone riboside (zebularine) and its fluorinated analogues. J. Med. Chem. 1991; 34: 3280
   PubMed Web of Science ®Google Scholar
• Wempen I., Miller N., Falco E. A., Fox J. J. Nucleosides. XLVII. Synthesis of some N4-substituted derivatives of 1-β-D-arabinofuranosyl cytosine and -5-fluorocytosine. J. Med. Chem. 1968; 11: 144
   PubMed Web of Science ®Google Scholar
• Kanai T., Ichino M. Pyrimidine nucleosides. 6. Syntheses and anticancer activities of N4-substituted 2,2′-anhydronucleosides. J. Med. Chem. 1974; 17: 1076
   Google Scholar
• Rosowsky A., Kim S. H., Ross J., Wick M M. Lipophilic 5′-(alkyl phosphate) esters of 1-β-D-arabinofuranosylcytosine and its N4-acyl and 2,2′-anhydro-3′-O-acyl derivatives as potential prodrugs. J. Med. Chem. 1982; 25: 171
   PubMed Web of Science ®Google Scholar
• Aoshima M., Tsukagoshi S., Sakurai Y., Oh-Ishi J., Ishida T., Kobayashi H. Antitumoractivities of newly synthesized N4-acyl-1-β-D-arabinofuranosylcytosine. Cancer Res. 1976; 36: 2726
   PubMed Web of Science ®Google Scholar
• Kataoka T., Sakurai Y. Effect and mode of action of N4-behenoyl-β-D-arabinofuranosylcytosine. Recent Results Cancer Res. 1980; 70: 147
   Google Scholar
• Tsuruo T., Tsukagoshi S., Sakurai Y. N4-palmitoyl- and N4-stearoyl-1-β-D-arabinofuranosylcytosine as new antitumor agent. Current Chemotherapy and infections Disease, J. D. Grassi. The American Society of Microbiology, Washington, DC 1980; 1591
   Google Scholar
• Kimura K., Ohno R., Amaki I., Hattori K., Hirota Y., Hoshino A., Ichimaru M., Ito M., Kimura I., Maekawa T., Masaoka T., Nakamura T., Ogawa M., Oguro M., Ohta K., Osamura S., Shimoyama M., Takaku F., Uzuka Y., Yamada K. Treatment of acute myelogenous leukemia in adults with N4-behenoyl-1-β-D-arabinofuranosylcytosine. Cancer 1985; 56: 1913
   PubMed Web of Science ®Google Scholar
• Patel K. R., Baldeschwieler J. D. Treatment of intravenously implanted Lewis lung carcinoma with liposome-encapsulated cytosine arabinoside and non-specific immuno- therapy. Int. J. Cancer 1984; 34: 415
   PubMed Web of Science ®Google Scholar
• Kobayashi T., Katakoa T., Tsukagoshi S., Sakurai Y. Enhancement of anti-tumor activity of 1-β-D-arabinofuranosylcytosine by encapsulation in liposomes. Int. J. Cancer 1977; 20: 581
   PubMed Web of Science ®Google Scholar
• Mayhew E., Papahadjopoulos D., Rustum Y. M., Dave C. Inhibition of tumor cell growth in vitro and in vivo by 1-β-D-arabinofuranosylcytosine entrapped within phospholipid vesicles. Cancer Res. 1976; 36: 4406
   PubMed Web of Science ®Google Scholar
• Funato K., Yoda R., Kiwada H. Contribution of complement system on destabilization of liposomes composed of hydrogenated egg phophatidylcholin in rat fresh plasma. Biochim. Biophys. Acta 1992; 1103: 198
   PubMed Web of Science ®Google Scholar
• Allen T. M., Hansen C., Martin F., Redemann C., Yau Young A. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim. Biophys. Acta 1991; 1066: 29
   PubMed Web of Science ®Google Scholar
• Gabizon A., Papahadjopoulos D. The role of surface charge and hydrophilic groups on liposome clearance in vivo. Biochim. Biophys. Acta 1992; 1103: 94
   PubMed Web of Science ®Google Scholar
• Allen T. M., Mehra T., Hansen C., Cheel Chin Y. Stealth liposomes: an improved sustained release system for 1-β-D-arabinofuranosylcytosine. Cancer Res. 1992; 52: 2431
   PubMed Web of Science ®Google Scholar
• Kim S., Khatibi S., Howell S. B., McCully C., Balis F. M., Poplack D. G. Prolongation of drug exposure in cerebrospinal fluid by encapsulation into DepoFoam. Cancer Res. 1993; 53: 1596
   PubMed Web of Science ®Google Scholar
• Rubas W., Supersaxo A., Weder H. G., Hartmann H. R., Hengartner H., Schott H., Schwendener R. A. Treatment of murine L1210 lymphoid leukemia and melanoma B16 with lipophilic cytosine arabinoside prodrugs incorporated into unilamellar liposomes. Int. J. Cancer 1986; 37: 149
   PubMed Web of Science ®Google Scholar
• Schwendener R. A., Pestalozzi B., Berger S., Schott H., Hengartner H., Sauter C. Treatment of acute myelogenous leukemia with liposomes containing N4-oleyl-cytosine arabinoside. Liposomes in the therapy of infectious disease and cancer, G Lopez-Berenstein, I J Fidler. Alan R. Liss Inc., New-York 1989; 95
   Google Scholar
• Schwendener R. A., Schott H. Treatment of L1210 murine leukemia with liposome-incorporated N4-hexadecyl-1-β-D-arabinofuranosyl cytosine. Int. J. Cancer 1992; 51: 466
   PubMed Web of Science ®Google Scholar
• Schott H., Häussler M. P., Schwendener R. A. Synthese von 4-Alkylcytosinnucleosiden und deren cytostatische Wirkung im L1210 Läukemiemodell der Maus. Liebigs Ann. Chem. 1994; 465
   Google Scholar
• Schwendener R. A., Horber D. H., Rentsch K., Hänseler E., Pestalozzi B., Sauter Chr. Preclinical and clinical Experience with Liposome-encapsulated Mitoxantrone. J. Liposome Res. 1994; 4: 605
   Google Scholar
• Hope M. J., Bally M. B., Webb G., Cullis P. R. Production of large unilamellar vesicles by a rapid procedure, characterization of size distribution, trapped volume and ability to maintain a membrane potential. Biochim. Biophys. Acta 1985; 812: 55
   PubMed Web of Science ®Google Scholar
• Geran R. I., Greenberg N. H., MacDonald M. M., Schumacher A. M., Abbott B. J. Protocols for screening chemical agents and natural products against animal tumors and other biological systems. 3. Ed., Cancer Chemother. Rep. 1972; 3: 47, Part III
   Google Scholar
• Chung B. H., Wilkinson T., Geer J. C., Segrest J. P. Preparative and quantitative isolation of plasma lipoproteins: rapid, single discontinuous density gradient ultracentrifugation in a vertical rotor. J. Lipid Res. 1980; 21: 284
   PubMed Web of Science ®Google Scholar
• Chapman J. M., Goldstein S., Lagrange D., Laplaud M. P. A density gradient ultracentrifugal procedure for the isolation of the major lipoprotein classes from human serum. J. Lipid Res. 1981; 22: 339
   PubMed Web of Science ®Google Scholar
• Spriggs D., Robbins G., Ohno Y., Kufe D. Detection of 1-β-D-arabinofuranosylcytosine incorporated into DNA in vivo. Cancer Res. 1987; 47: 6532
   PubMed Web of Science ®Google Scholar
• Bradford M. M. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976; 72: 248
   PubMed Web of Science ®Google Scholar
• Mosmann T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol. Meth. 1983; 65: 55
   PubMed Web of Science ®Google Scholar
• Momparler R. L., Onetto-Pothier N., Bouffard D. Y., Momparler L. Cellular pharmacology of 1-β-D-arabinofuranosylcytosine in human myeloid, B-lymphoid and T-lymphoid leukemic cells. Cancer Chemother. Pharmacol. 1990; 27: 141
   Google Scholar
• Kleinfeld A. M., Storch J. Transfer of long-chain fluorescent fatty acids between small and large unilamellar vesicles. Biochemistry 1993; 32: 2053
   PubMed Web of Science ®Google Scholar
• Richieri G. V., Anel A., Kleinfeld A. M. Interactions of long-chain fatty acids and albumin: Determination of free fatty acid levels using the fluorescent probe ADIFAB. Biochemistry 1993; 32: 7574
   PubMed Web of Science ®Google Scholar
• King M. E., Naporn A., Young B., Howell S. B. Modulation of cytarabine uptake and toxicity by dipyridamole. Cancer Treat. Rep. 1984; 68: 361
   Google Scholar
• Richel D. J., Colly L. P., Arkesteijn G. J., Arentsen H. M., Kerster M. G., Rietter P. M., Willemze R. Substrate-specific deoxycytidine kinase deficiency in 1-β-D-arabinofuranosylcytosine-resistant leukemic cells. Cancer Res. 1990; 50: 6515
   PubMed Web of Science ®Google Scholar
• Stegmann A. P., Honders M. W., Kester M. G., Landegent J. E., Willemze R. Role of deoxycytidine kinase in an in vitro model for AraC- and DAC-resistance: substrate-enzyme interactions with deoxycytidine, 1-β-D-arabinofuranosylcytosine and 5-aza-2′-deoxycytidine. Leukemia 1993; 7: 1005
   Google Scholar